Alto Neuroscience (NYSE:ANRO) Price Target Raised to $55.00

Alto Neuroscience (NYSE:ANRO) had its target price boosted by HC Wainwright from $50.00 to $55.00 in a research note published on Monday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Alto Neuroscience’s Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.80) EPS, Q1 2027 earnings at ($0.93) EPS, Q2 2027 earnings at ($0.97) EPS, Q3 2027 earnings at ($1.00) EPS, Q4 2027 earnings at ($0.96) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($4.39) EPS, FY2029 earnings at ($3.25) EPS and FY2030 earnings at ($1.29) EPS.

Several other equities research analysts also recently issued reports on ANRO. Wedbush increased their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Wall Street Zen upgraded Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Robert W. Baird lowered their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Wolfe Research started coverage on Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Finally, Bank of America began coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target for the company. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.25.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO opened at $34.95 on Monday. The company’s fifty day moving average is $26.85 and its two-hundred day moving average is $23.18. The company has a market cap of $1.37 billion, a P/E ratio of -14.44 and a beta of 1.06. Alto Neuroscience has a 12-month low of $3.32 and a 12-month high of $35.41. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08. Equities analysts expect that Alto Neuroscience will post -2.68 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

Hedge funds and other institutional investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. grew its stake in Alto Neuroscience by 14,567.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after purchasing an additional 211,222 shares in the last quarter. Jennison Associates LLC acquired a new position in Alto Neuroscience in the 1st quarter worth about $8,687,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Alto Neuroscience during the 1st quarter worth about $538,000. Orbimed Advisors LLC raised its stake in shares of Alto Neuroscience by 34.0% during the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock worth $3,765,000 after purchasing an additional 42,500 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its holdings in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after buying an additional 225,500 shares during the last quarter.

More Alto Neuroscience News

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $2.80 from $2.98 and lifted its FY2027 estimate to a loss of $3.87 from $4.39. Quarterly estimates were also improved, including Q3 2026 to a loss of $0.67 from $0.72 and Q4 2026 to a loss of $0.68 from $0.71. Alto Neuroscience Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: The analyst also reduced projected losses for 2027 through 2030, including FY2028 to a loss of $4.39 from $4.81, FY2029 to a loss of $3.25 from $3.50, and FY2030 to a loss of $1.29 from $1.53. These changes point to expectations for better long-term financial performance.
• Positive Sentiment: HC Wainwright maintained its $55 price objective, which remains above Alto Neuroscience’s recent trading level. The stock has climbed substantially over the past year and is trading close to its 52-week high, indicating strong investor momentum.
• Neutral Sentiment: Despite the improved forecasts, Alto Neuroscience is still expected to report losses in every period listed. The company’s current-year consensus estimate remains a loss of $2.71 per share, so the investment case continues to depend heavily on clinical and commercial progress.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.